Zoledronic acid induces autophagic cell death in human prostate cancer cells

Journal of Urology

Volumn 185, Issue 4, 2011, Pages 1490-1496

  Lin, Ji Fan ^a   Lin, Yi Chia ^a,b   Lin, Yi Hsuan ^a   Tsai, Te Fu ^a,b   Chou, Kuang Yu ^a,b   Chen, Hung En ^a   Hwang, Thomas I Sheng ^a,b,c  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

apoptosis; autophagy; prostate; prostatic neoplasms; zoledronic acid

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACRIDINE ORANGE; CASPASE 3; CELL PROTEIN; PROTEIN LC3 II; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PHAGOSOME; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; STAINING; WESTERN BLOTTING;

AUTOPHAGY; BONE DENSITY CONSERVATION AGENTS; CELLS, CULTURED; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS;

EID: 79952696802     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.11.045     Document Type: Article

References (30)

1. Wolf AM, Wender RC, Etzioni RB et al: American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60: 70.
2. Loblaw DA, Virgo KS, Nam R et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596.
3. Petrylak DP, Tangen CM, Hussain MH et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513.
4. Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165.
5. Sharifi N, Gulley JL and Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238.
6. Lipton A: Should bisphosphonates be utilized in the adjuvant setting for breast cancer? Breast Cancer Res Treat 2010.
7. Terpos E, Sezer O, Croucher PI et al: The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20: 1303.
8. Saad F and Schulman CC: Role of bisphosphonates in prostate cancer. Eur Urol 2004; 45: 26.
9. Saad F, Gleason DM, Murray R et al: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879.
10. Dumon JC, Journe F, Kheddoumi N et al: Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004; 45: 521.
11. Coxon JP, Oades GM, Kirby RS et al: Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004; 94: 164.
12. Montague R, Hart CA, George NJ et al: Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. Eur Urol 2004; 46: 389.
13. Lum JJ, Bauer DE, Kong M et al: Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005; 120: 237.
14. Eisenberg-Lerner A, Bialik S, Simon HU et al: Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009; 16: 966.
15. Hippert MM, O'Toole PS and Thorburn A: Autophagy in cancer: good, bad, or both? Cancer Res 2006; 66: 9349.
16. Kanzawa T, Kondo Y, Ito H et al: Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 2003; 63: 2103.
17. Herman-Antosiewicz A, Johnson DE and Singh SV: Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells. Cancer Res 2006; 66: 5828.
18. Yi-Chia L, Ji-Fan L, Te-Fu T et al: 1197 Zoledronic acid enhances growth inhibition and apoptosis in both hormone-refractory and hormone-sensitive prostate cancer cell lines. J Urol 2010; 183: e463.
19. Kondo Y, Kanzawa T, Sawaya R et al: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005; 5: 726.
20. Yo YT, Shieh GS, Hsu KF et al: Licorice and licochalcone-A induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway. J Agric Food Chem 2009; 57: 8266.
21. Shintani T and Klionsky DJ: Autophagy in health and disease: a double-edged sword. Science 2004; 306: 990.
22. Hoyer-Hansen M and Jaattela M: Autophagy: an emerging target for cancer therapy. Autophagy 2008; 4: 574.
23. Rosenfeldt MT and Ryan KM: The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med 2009; 11: e36.
24. Hu H, Chai Y, Wang L et al: Pentagalloylglucose induces autophagy and caspase-independent programmed deaths in human PC-3 and mouse TRAMP-C2 prostate cancer cells. Mol Cancer Ther 2009; 8: 2833.
25. Maiuri MC, Galluzzi L, Morselli E et al: Autophagy regulation by p53. Curr Opin Cell Biol 2010; 22:181.
26. Korkhov VM: GFP-LC3 labels organised smooth endoplasmic reticulum membranes independently of autophagy. J Cell Biochem 2009; 107: 86.
27. Kuma A, Matsui M and Mizushima N: LC3, an autophagosome marker, can be incorporated into protein aggregates independent of autophagy: caution in the interpretation of LC3 localization. Autophagy 2007; 3: 323.
28. Ciechomska IA and Tolkovsky AM: Non-autophagic GFP-LC3 puncta induced by saponin and other detergents. Autophagy 2007; 3: 586.
29. Wu YT, Tan HL, Shui G et al: Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem 2010; 285: 10850.
30. Caraglia M, Marra M, Leonetti C et al: R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and decreased Bcl-2 and bad phosphorylation. J Cell Physiol 2007; 211: 533.